TransMedics Group, Inc. TMDX Lung Product — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about TransMedics Group, Inc.'s lung product — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TransMedics Group, Inc.'s lung product — revenue?
- TransMedics Group, Inc. (TMDX) reported lung product — revenue of $2.82M in Q1 2026.
- How has TransMedics Group, Inc.'s lung product — revenue changed year-over-year?
- TransMedics Group, Inc.'s lung product — revenue decreased by 29.6% year-over-year, from $4.01M to $2.82M.
- What is the long-term trend for TransMedics Group, Inc.'s lung product — revenue?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s lung product — revenue has grown at a 8.6% compound annual growth rate (CAGR), from $10.67M to $14.86M.
- What does lung product — revenue mean?
- This metric represents the total gross sales generated from the sale and service of lung-specific organ perfusion and monitoring technologies. It serves as a key indicator of the company's market penetration and clinical adoption rates within the pulmonary transplant segment. Tracking this revenue stream helps investors assess the commercial success of the lung-focused product portfolio relative to broader organ transplant market demand.